Thromb Haemost 2018; 118(07): 1176-1184
DOI: 10.1055/s-0038-1655767
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia

Christian Schoergenhofer
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Michael Schwameis
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Georg Gelbenegger
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Nina Buchtele
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Barbara Thaler
Department of Cardiology, Medical University of Vienna, Vienna, Austria
,
Marion Mussbacher
Department of Thrombosis Research and Vascular Biology, Medical University of Vienna, Vienna, Austria
,
Gernot Schabbauer
Department of Thrombosis Research and Vascular Biology, Medical University of Vienna, Vienna, Austria
,
Johann Wojta
Department of Cardiology, Medical University of Vienna, Vienna, Austria
,
Petra Jilma-Stohlawetz
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
,
Bernd Jilma
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
› Author Affiliations
Funding This work was supported by the Austrian Science Funds (FWF) with the grant number SFB54P04.
Further Information

Publication History

16 January 2018

15 April 2018

Publication Date:
04 June 2018 (eFirst)

Abstract

The protease-activated receptor-1 (PAR-1) is critically involved in the co-activation of coagulation and inflammatory responses. Vorapaxar is a reversible, orally active, low molecular weight, competitive antagonist of PAR-1.We investigated the effects of PAR-1 inhibition by vorapaxar on the inflammatory response, the activation of coagulation, fibrinolysis and endothelium during experimental endotoxemia. In this randomized, double blind, crossover trial, 16 healthy volunteers received a bolus infusion of 2 ng/kg lipopolysaccharide (LPS) ± placebo/vorapaxar with a washout period of 8 weeks. Vorapaxar dosing was guided by thrombin receptor-activating peptide-6-induced whole blood aggregometry. Participants received 10 mg vorapaxar or placebo as an initial dose and, depending on the aggregometry, potentially an additional 10 mg. Goal was > 80% inhibition of aggregation compared with baseline. Vorapaxar significantly reduced the LPS-induced increase in pro-thrombin fragments F1 + 2 by a median of 27% (quartiles: 11–49%), thrombin–anti-thrombin concentrations by 22% (–3 to 46%) and plasmin–anti-plasmin levels by 38% (23–53%). PAR-1 inhibition dampened peak concentrations of tumour necrosis factor -α, interleukin-6 and consequently C-reactive protein by 66% (−11–71%), 50% (15–79%) and 23% (16–38%), respectively. Vorapaxar decreased maximum von Willebrand factor levels by 29% (26–51%) and soluble E-selectin concentrations by 30% (25–38%) after LPS infusion. PAR-1 inhibition did not affect thrombomodulin, soluble P-selectin and platelet factor-4 concentrations.

PAR-1 inhibition significantly reduced the activation of coagulation, fibrinolysis, the inflammatory response and endothelial activation during experimental human endotoxemia.

Authors' Contributions

C.S. and B.J. designed the trial. All authors were involved in the conduct of the trial. The statistical analysis was performed by C.S. and B.J. All authors were involved in the interpretation of the trial results. C.S. and B.J. drafted the manuscript. All authors critically revised the manuscript and approved the final version for publication.


Note

This work was performed at the Department of Clinical Pharmacology, Medical University of Vienna, Austria.


Supplementary Material